14 others would like to attend.
Register Now
Loews Philadelphia Hotel, 1200 Market St, Philadelphia, PA 19107
Event info
For more information and to register: HeartInDiabetes
Overall Program Objectives/Discussion Topics
This CME program is a unique medical conference bringing together world-renowned clinical leaders in diabetes and cardiovascular disease. The program is designed to evaluate the state of the art clinical data and research while focusing on the management of the heart and kidney in diabetes. The goal is to align cardiologists, endocrinologists, diabetologists, iridologists, and nephrologists in their understanding and development of appropriate comprehensive clinical management plans for very high-risk patients.
Upon completion of this meeting, participants should be able to:
- Describe the relationship between diabetes, obesity, and the heart
- Explain the roles of diabetes and obesity in the development of kidney disease, retinopathy, CVD, and arrhythmia
- Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, and hyperglycemia
- Understand cardiovascular outcomes trials (CVOT) and the role of real-life big data in assessing management
- Evaluate antihyperglycemic CVOT results, specifically the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular morbidity and mortality in patients with T2D
- Understand CHF in diabetes to implement best practices for the management of CHF
- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Explain the role of lipids, in particular, LDL-C and non-HDL-C, in the development of atherosclerosis
- Describe the role of PCSK9 in lipid homeostasis and the impact of monoclonal antibody therapy with PCSK9 inhibitors on cardiovascular disease
- Understand risk categories and determine appropriate targets of lipid-lowering therapy as outlined in the AACE 2017 Dyslipidemia Management Clinical Guidelines
- Appropriately diagnose and treat hypercoagulation and thrombosis as consequences of insulin resistance, inflammation, and diabetes
- Address the proper anticoagulation agents in the management of the high-risk patient
- Understand the combination treatments of CHF, hypertension, and lipid disorders
- Discuss the role of combination therapy in the management of obesity and diabetes with a focus on incretin- and SGLT2 inhibitor-based treatment
Initiative/Goal
- To develop a platform to address the clinical science of the Heart in Diabetes
- To identify the clinical implications of state-of-the-art clinical research on cardiovascular and kidney disease in diabetes
- To further advance the discussion between Cardiologists, Endocrinologists, Nephrologists, Lipidologists, and other interested clinicians, while developing an ongoing interaction in the management and prevention of heart disease in diabetes and cardiometabolic conditions
Target Audience
Cardiologist Endocrinologists, Nephrologists Diabetologists, Lipidologists Internists, Family Clinicians, and other clinicians who are interested in the Heart in Diabetes.
14 others would like to attend.
Register Now